The FDA approved the first generic version of the cancer drug Doxil. The drug is made by Sun Pharmaceuticals, the same company that makes Lipodox. Lipodox importation is allowed temporarily … Continue reading →

A new study of mice with prostate cancer indicated that stress can hinder the effectiveness of anti-cancer therapies. In this mouse model, the use of beta-blockers did prevent stress from … Continue reading →

A small study of 35 pre-menopausal women with gynecologic cancers (ovarian, cervical and uterine) showed a decrease in bone mineral density after treatment. Women with cervical cancer appeared to have … Continue reading →

A new paper authored by two Food and Drug Administration (FDA) employees argues that the recent spate of drug shortages was caused by numerous factors, all of which can be … Continue reading →

A study of 425 Stage III and IV ovarian cancer patients had either primary debulking surgery or interval debulking surgery. Interval debulking surgery did not appear to increase the risk … Continue reading →

A new study indicates a direct link between higher blood calcium levels and presence of ovarian cancer. Specifically, “women who were later diagnosed with ovarian cancer and women who later … Continue reading →

New data has been released showing that the number of women who get ovarian cancer has decreased as well as the number of women who die from the disease. Since … Continue reading →

Due to the current crisis in Washington regarding the budget, appropriations and debt ceiling, federal funding for cancer research is in jeopardy. Due to the sequester, cancer research may take … Continue reading →

In an analysis of more than 4,000 women with ovarian cancer, it appears that some hormonal and reproductive factors may affect tumor aggressiveness. The study showed that increased age was … Continue reading →

A study of 149 women with platinum sensitive ovarian cancer, half treated with carboplatin and paclitaxel or gemcitabine, half with that treatment plus pertuzumab, showed that the addition of pertuzumab … Continue reading →